

CURRICULUM VITAE

PERSONAL

NAME(姓名，含英譯)

沈峰志

PROFESSIONAL APPOINTMENT (現職，含英譯)

高雄長庚醫院 內分泌暨新陳代謝科

EDUCATION(學歷)

中國醫藥大學 醫學系

WORKING EXPERIENCE (經歷)

高雄長庚醫院 內分泌暨新陳代謝科 主治醫師

MAJOR RESEARCH AREA(研究領域)

糖尿病，粒線體

PUBLICATION(In the nearest 5 years)(發表、出版物)

1. **Shen FC**, Weng SW, Tsao CF, Lin HY, Chang CS, Lin CY, Lian WS, Chuang JH, Lin TK, Liou CW, Wang PW. Early intervention of N-acetylcysteine better improves insulin resistance in diet-induced obesity mice. *Free Radic Res.* 2018 Dec;52(11-12):1296-1310.
2. Chen SM, **Shen FC**, Chen JF, Chang WD, Chang NJ. Effects of Resistance Exercise on Glycated Hemoglobin and Functional Performance in Older Patients With Comorbid Diabetes Mellitus and Knee Osteoarthritis: A Randomized Trial. *Int J Environ Res Public Health.* 2019 Dec 27;17(1):224. doi: 10.3390/ijerph17010224.
3. Chen YN, Wang PW, Tung SC, Kuo MC, Weng SW, Chou CK, Chang CM, Tsa CJ, Taso CF, **Shen FC**, Chen JF. Association Between Pro12Ala Polymorphism and Albuminuria in Type 2 Diabetic Nephropathy. *J Diabetes Investig.* 2020 Jan 7. doi: 10.1111/jdi.13208.
4. Yang YT, Chen JF, Tung SC, Kuo MC, Weng SW, Chou CK, **Shen FC**, Chang CM, Tsai CJ, Taso CF, Wang PW. Long-term Outcome and Prognostic Factors of Single-Dose Radioiodine Therapy in Patients With Graves' Disease. *J Formos Med Assoc.* 2020 May;119(5): 925-932. doi: 10.1016/j.jfma.2020.01.014.
5. Lin HY, Weng SW, **Shen FC**, Chang YH, Lian WS, Hsieh CH, Chuang JH, Lin TK, Liou CW, Chang CS, Lin CY, Su YJ, Wang PW. Abrogation of Toll-Like Receptor 4 Mitigates Obesity-Induced Oxidative Stress, Proinflammation, and Insulin Resistance Through Metabolic Reprogramming of Mitochondria in Adipose Tissue. *Antioxid Redox Signal.* 2020 Jul 10;33(2):66-86. doi: 10.1089/ars.2019.7737
6. Chang YH, Lin HY, **Shen FC**, Su YJ, Chuang JH, Lin TK, Liou CW, Lin CY, Weng SW, Wang PW. The Causal Role of Mitochondrial Dynamics in Regulating Innate Immunity in Diabetes. *Front Endocrinol (Lausanne).* 2020 Jul 29;11:445. doi: 10.3389/fendo.2020.00445.eCollection 2020



7. Tsao CF, Chang YH, **Shen FC**, Su YJ, Lin HY, Chang CS, Lin CY, Lian WS, Chuang JH, Lin TK, Liou CW, Wang PW, Weng SW. Legacy Effect of Antioxidant N-acetylcysteine in Cellular Senescence of Diet-induced Obesity Mice. *Curr Mol Med* . 2020 Nov 12. doi: 10.2174/1566524020999201113101738. Online ahead of print.
8. **Shen FC**, Cheng BC, Chen JF. Peri-renal fat thickness is positively associated with the urine albumin excretion rate in patients with type 2 diabetes. *Obes Res Clin Pract*. 2020;14(4):345-349.
9. **Shen FC**, Weng SW, Tsai MH, Su YJ, Li SC, Chang SJ, Chen JF, Chang YH, Liou CW, Lin TK, Chuang JH, Lin CY, Wang PW. Mitochondrial haplogroups have a better correlation to insulin requirement than nuclear genetic variants for type 2 diabetes mellitus in Taiwanese individuals. *J Diabetes Investig*. 2022 Jan;13(1):201-208.
10. Hsiao YT, **Shen FC**, Weng SW, Wang PW.; Chen YJ, Lee JJ. Multiple Single Nucleotide Polymorphism Testing Improves the Prediction of Diabetic Retinopathy Risk with Type 2 Diabetes Mellitus. *J. Pers. Med.* **2021**, *11(8)*, 689
11. Chen NC, Chen CL, **Shen FC**. The risk factors of severe hypoglycemia in older patients with dementia and type 2 diabetes mellitus. *J. Pers. Med.* **2022**, *12(1)*, 67.
12. Su YJ, Li FA, Jim Sheu JC, Sung-Chou Li, Weng SW, **Shen FC**, Chang YH, Chen HY, Liou CW, Lin TK, Chuang JH, Wang PW. A Study on MDA5 Signaling in Splenic B Cells from an Imiquimod-Induced Lupus Mouse Model with Proteomics. *Cells* **11** (21), 3350.
13. Weng SW, Chen WC, **Shen FC**, Wang PW, Chen JF, Liou CW. Circulating growth differentiation factor 15 is associated with diabetic neuropathy. *J Clin Med*. 2022 May 27;11(11):3033
14. Chen YN, Tsai JR, Chen JF, **Shen FC**. Hypocalcemia Is a Common Risk Factor for Osteoporosis in Taiwanese Patients with Cushing's Syndrome. *Int J Environ Res Public Health*. 2022 Nov 30;19(23):16064.
15. Weng SW, Wu JC, **Shen FC**, Chang YH, Su YJ, Lian WS, Tai MH, Su CH, Chuang JH, Lin TK, Liou CE, Chu TH, Kao YH, Wang FS, Wang PW. Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation. *Diabetologia*. 2023 May;66(5):913-930

From Guidelines to Practice: Implementing Single-Pill Combination for Improved
Chronic Disease Medication in Patients with Diabetic (Clinical Perspective)

糖尿病患者的慢性疾病改善，以複方藥物起始治療落實指引之建議 (以臨床醫師的觀點)

沈峰志 醫師

高雄長庚醫院 內分泌暨新陳代謝科

【摘要】

糖尿病患者，甚至更廣泛的包含至高血壓、高血脂及高血糖的三高族群，其疾病的成因都是由多種病因同時存在所造成的，治療時可依據不同的生理或藥理機轉來治療。因此在各國三高的治療指引之中，常引入早期複方起始治療的概念。讓病人延緩疾病的進程，預防如器官損害、血管栓塞、中風...等重大傷病的發生。

臨床面對的病人，尤其在高風險的狀況下，需要積極的治療及處置，早期使用複方藥物的合併治療如何落實在日常照護之中，是每個醫療人員切身的議題，這裡將分享個人的臨床經驗，與大家一起交流討論。